ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MBIO / news
CMND (47) ERNA (33) SXTP (38) GRI (34) ⌘ Pro Terminal →

Why MBIO Stock surged +3.72% Today — RQD Quant Desk Flash

$0.42 +3.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.42

Mustang Bio Inc. (MBIO) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MBIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Mustang Bio Inc. (NASDAQ: MBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.42 (+3.72% 1D, market cap $3.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MBIO ranks #451 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MBIO compare to CMND and ERNA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBIO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMND (Clearmind Medicine Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.1M) and ERNA (Ernexa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, MBIO leads on earnings multiple (N/A) while MBIO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MBIO?
▼

Per MBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680048), Mustang Bio Inc. generated $6.8M in revenue (-85.0% YoY), -$1.9M in net income, and -$5.3M in free cash flow against $17.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.42 (+0.48%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D
Cash (4)Whales (12)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-7.1% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE MBIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MBIO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY MBIO SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$0.37+2.7% Next Q
Q2 (-2Q)
36
Grade E$0.38-5.3% Next Q
Q3 (-1Q)
38
Grade E$0.36+16.7% Next Q
Current
41
Grade D-$0.42-7.2% Hist 90D α
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MBIO currently carries a cautious 41/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.46) and Max Pain ($0.44) forces dealer call-delta covering toward $1.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why MBIO Stock surged +3.72% Today — RQD Quant Desk Flash

Mustang Bio Inc. (MBIO) surged +3.72% to $0.42, trading at 6% of its 52-week range ($0.35 – $1.43). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 6% of its 52-week range ($0.35 – $1.43) with RSI-14 at 52.2 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.42 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MBIO Headlines & Catalysts
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. Market

TradingKey report covering Mustang Bio Inc. (MBIO) market action, institutional positioning, and fundamental catalysts.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MBIO)

  • ✓Walkthrough of MBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -45.45%▲ RESISTANCE BREAKOUT
2026-11-04O $0.41H $0.42L $0.41C $0.42VOL 34.2K
RES: $0.42SUP: $0.33SMA50: $0.46SMA200: $0.68
$1.28$1.03$0.78$0.52$0.27RES $0.42SUP $0.33$0.422026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MBIO Butterfly Map → + Track MBIO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -85.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MBIO)

Health Care Rank #451 of 1015 ⚔️ CMND vs MBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MBIO vs. CMND, ERNA, SXTP, GRI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Mustang Bio Inc. (MBIO) ranks #451 by composite RQD confidence (41/100, grade D-) and #972 by equity capitalization ($3.1M). Within this direct 5-issuer industry benchmark cohort, MBIO leads on earnings valuation at N/A trailing P/E, while MBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CMND currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MBIO at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MBIO ACTIVE
Mustang Bio Inc.
D- 41/100 — — -35.0% +3.72% $3.1M Benchmark Subject
CMND
Clearmind Medicine Inc.
D 47/100 — — — -1.27% $3.1M /cmnd-vs-mbio →
ERNA
Ernexa Therapeutics Inc.
E 33/100 — — -35.0% -1.01% $3.2M /erna-vs-mbio →
SXTP
60 Degrees Pharmaceuticals Inc.
D- 38/100 — 22.3% -35.0% -3.65% $3.2M /sxtp-vs-mbio →
GRI
GRI Bio Inc.
E 34/100 — — -35.0% -4.57% $3.2M /gri-vs-mbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680048 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mustang Bio Inc. (MBIO) reported GAAP revenue of $6.8M (-85.0% vs. FY2024 revenue of $45.5M , and -95.1% cumulative change since FY2023) , GAAP net income of -$1.9M, operating cash flow of -$5.3M, and free cash flow of -$5.3M (+53.9% YoY). On the balance sheet, MBIO closed FY2025 with $17.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.8M -$1.9M -$5.3M -$5.3M $17.6M —
FY2024 (FY) 2024-12-31 $45.5M -$15.8M -$11.4M -$11.4M $9.3M —
FY2023 (FY) 2023-12-31 $137.9M -$51.6M -$49.5M -$49.5M — —

3. MBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Mustang Bio Inc. (NASDAQ: MBIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.42 (+3.72% 1D, market cap $3.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MBIO ranks #451 in composite RQD confidence.

How does MBIO compare to CMND and ERNA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MBIO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMND (Clearmind Medicine Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $3.1M) and ERNA (Ernexa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, MBIO leads on earnings multiple (N/A) while MBIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MBIO?

Per MBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680048), Mustang Bio Inc. generated $6.8M in revenue (-85.0% YoY), -$1.9M in net income, and -$5.3M in free cash flow against $17.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

MBIO last traded at $0.42 (+3.72% on volume of 34,155 shares), positioning the stock -8.70% below its 50-day simple moving average ($0.46) and -38.24% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.35 to $1.43, MBIO sits at the 6.5% percentile with a 14-day RSI of 52.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.47).

Direct Sub-Reports: MBIO RQD Cockpit MBIO 12M Forecast MBIO Earnings & Move MBIO Dividends & DRIP MBIO Insiders & 13F MBIO Whale Options MBIO Profit Sankey MBIO News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MBIO — Mustang Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Mustang Bio Inc. (MBIO) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.42 (+3.72% 1D, market capitalization $3.1M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Mustang Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The SEC financials report revenue of — across the FY 2023, FY 2024, and FY 2025 periods, so the company is not generating reported revenue in the provided data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Mustang Bio Inc. (MBIO) reported $6.8M in annual revenue (up from $45.5M in FY2024, -85.0% YoY) and -$1.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($137.9M revenue, -$51.6M net income) through FY2025, MBIO scaled operating cash flow to -$5.3M and free cash flow to -$5.3M, backed by $17.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 12/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $0.35 – $1.43 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MBIO carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MBIO sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.8M and free cash flow of -$5.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MBIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mustang Bio Inc. (MBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MBIO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MBIO Bull vs. Bear Conversation Board — What's Your Call at $0.42?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MBIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MBIO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $0.47 (+17.5%)
📌 Pinned Debate

Reported cash rose to $17.3M in FY 2025 while net loss narrowed to -$1.9M from -$51.6M in FY 2023.

The street is overcomplicating Mustang Bio Inc. (MBIO). Reported cash rose to $17.3M in FY 2025 while net loss narrowed to -$1.9M from -$51.6M in FY 2023.. With an RQD score of 41/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.43.

EarningsSniper 🐂 BULL

@ShortSeller_Dan Shorting a 12/20 institutional whale-flow stock at $0.40 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.30 (-25.0%)
Spot @ $0.40

With a 39 RQD score, ROIC of -35%, zero FCF yield, and a $0.39 price amid a Nasdaq bid-price reprieve, the balance sheet and flow profi

Careful chasing MBIO at $0.40. With a 39 RQD score, ROIC of -35%, zero FCF yield, and a $0.39 price amid a Nasdaq bid-price reprieve, the balance sheet and flow profile look vulnerable.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.30 on multiple compression.

LIVE TAPE